Category: What’s New in MS Research

The studies featured in this edition of “What’s New in MS Research” speak to progress made and progress awaited. We start out by announcing two new disease-modifying therapies that are or soon will be available through one’s healthcare provider.

Experts in every aspect of multiple sclerosis (MS) gathered in Amsterdam, The Netherlands, in late October 2022 to unveil research results and share ideas at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). With more than 1,200 bridges, the Dutch capital was an appropriate location for a meeting dedicated to connecting the findings from laboratory research and clinical trials to enhancements in patient care.

If there’s one theme that emerges from the study findings that follow, it’s how much people with multiple sclerosis (MS) can do to enhance their health and wellbeing. We know that can be a challenging task, as many aspects of the disease and its course remain beyond a person’s control. Nonetheless, the research summarized here provides abundant reason for encouragement.

Hope filled the halls of the Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) during the first week of June, when MS clinicians, researchers, and advocates from across the country and abroad convened to exchange the latest findings in MS research.

Reviewed by MSAA Chief Medical …

Reviewed by MSAA Chief Medical …

Reviewed by MSAA Chief Medical …

Reviewed by MSAA Chief Medical …

Reviewed by MSAA Chief Medical …

Reviewed by MSAA Chief Medical …